Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
published : Previous years tags : Covid-19 save search
Novavax Presents Data on Updated COVID-19 Vaccine and Progress to Date on its COVID-19-Influenza Combination Vaccine Candidate at World Vaccine Congress 2024
Published: 2024-04-01 (Crawled : 12:00) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: -1.03%
H: 0.62%
C: -3.53%
covid-19 candidate vaccine congress world
GeoVax to Present Data on GEO-CM04S1, a Next Generation Covid-19 Vaccine, at the World Vaccine Congress
Published: 2024-03-28 (Crawled : 13:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 4.21%
H: 1.01%
C: 1.01%
cm04 covid-19 vaccine congress world
Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Published: 2024-03-27 (Crawled : 11:00) - globenewswire.com
AVIR | $3.7 0.0% 220K
|
Health Technology
|
| O: 3.71%
H: 3.45%
C: 2.3%
covid-19 bemnifosbuvir antiviral pharmaceuticals global trial
Moderna Achieves Positive Interim Results from Phase 3 Trial of Next-Generation COVID-19 Vaccine
Published: 2024-03-26 (Crawled : 12:00) - biospace.com/
MRNA S | $101.44 -0.55% -0.55% 2.6M
|
Health Technology
|
| O: 1.29%
H: 0.0%
C: -3.93%
covid-19 vaccine positive trial results
Invivyd Announces FDA Authorization for Emergency Use of PEMGARDA™ (Formerly VYD222) for Pre-exposure Prophylaxis (PrEP) of COVID-19
Published: 2024-03-22 (Crawled : 19:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
| Email alert
Add to watchlist
vyd222 covid-19 fda authorization
Global Medical Device Connectivity Market Poised for Substantial Growth: In-Depth Analysis Reflects Impacts of COVID-19 and Predicts Surge through 2029
Published: 2024-03-21 (Crawled : 15:30) - prnewswire.com
ORCL | $114.88 -0.97% 0.01% 8.2M
|
Technology Services
|
| O: 0.99%
H: 1.73%
C: -1.16%
MDT | $79.48 0.37% -0.29% 6.7M
|
Health Technology
|
| O: -0.56%
H: 0.5%
C: -0.19%
INFY | $16.81 1.82% -1.31% 15M
|
Technology Services
|
| O: -3.06%
H: 0.76%
C: -0.76%
LTRX | $3.105 -1.43% -1.45% 150K
|
Distribution Services
|
| O: 1.12%
H: 1.67%
C: 0.28%
DGII | $29.32 -0.95% -0.95% 170K
|
Electronic Technology
|
| O: 0.98%
H: 0.77%
C: 0.37%
CSCO | $48.33 0.46% 0.46% 20M
|
Technology Services
|
| O: 0.32%
H: 0.97%
C: 0.34%
covid-19 device global medical market
Therapeutic Solutions International Granted Patent on Commercially Available QuadraMune® Nutraceutical for Increasing Natural Killer Cell Immunity in COVID-19 Patients
Published: 2024-03-04 (Crawled : 16:00) - biospace.com/
TSOI | $0.0007 0.0% 33M
|
Manufacturing
|
| O: 10.0%
H: 18.18%
C: 9.09%
covid-19 quadramune patent natural granted international cell solutions
Novavax and Gavi Reach Settlement on 2021 COVID-19 Vaccine Advance Purchase Agreement
Published: 2024-02-22 (Crawled : 11:00) - prnewswire.com
NVAX | $3.99 2.57% 2.51% 2.9M
|
Health Technology
|
| O: 12.06%
H: 22.42%
C: 9.42%
covid-19 vaccine reach agreement
Bioxytran’s Oral Antiviral Drug to Enter Dose Optimization Clinical Trial for COVID-19
Published: 2024-02-21 (Crawled : 13:00) - globenewswire.com
BIXT A | $0.1285 490.75% 32K
|
Professional, Scientific, and T...
|
| O: 0.0%
H: 0.09%
C: -5.9%
covid-19 drug antiviral trial
Global Cruise Industry Trends Report 2024: COVID-19 Impacts, Company Case Studies, Sector Deals, Advertisement Activity, Challenges and Opportunities
Published: 2024-02-19 (Crawled : 23:00) - prnewswire.com
ARVL | News | $0.49 0.37% 2.5M
|
Manufacturing
| Email alert
Add to watchlist
covid-19 company report global trends
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
Published: 2024-02-12 (Crawled : 12:00) - globenewswire.com
GRTS | $0.7414 -0.31% -0.31% 1.5M
|
Health Technology
|
| O: 0.89%
H: 3.42%
C: -0.88%
covid-19 update trial
COVID-19 Cliff and Skyrocketing GLP-1 Drug Sales Highlight Q4 2023 Earnings
Published: 2024-02-09 (Crawled : 17:00) - biospace.com/
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: -0.68%
H: 0.0%
C: 0.0%
SNY | News | $46.32 2.05% 2.01% 3.3M
|
Health Technology
|
| O: 1.11%
H: 0.0%
C: 0.0%
covid-19 sales drug
GeoVax Reports Positive Interim Data From Phase 2 Clinical Trial of GEO-CM04S1 as a Universal Covid-19 Vaccine Booster
Published: 2024-02-06 (Crawled : 14:00) - globenewswire.com
GOVX | $1.59 4.61% 4.4% 19K
|
Health Technology
|
| O: 2.77%
H: 2.69%
C: 1.92%
cm04 covid-19 vaccine universal geo-cm04s1 positive trial
Ainos Submits Clinical Hold Complete Response to US FDA to Resolve the Deficiencies on Investigational New Drug Phase II Trial of its VELDONA Formulation Against Mild COVID-19 Symptoms
Published: 2024-02-05 (Crawled : 15:00) - biospace.com/
AIMD | $1.03 1.92% 21K
|
Manufacturing
|
| O: 11.65%
H: 0.0%
C: -6.09%
covid-19 fda drug resolve trial response
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster - February 5, 2024
Published: 2024-02-05 (Crawled : 14:30) - biospace.com/
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
New COVID-19 sa-mRNA Results from CSL and Arcturus Therapeutics Demonstrate Longer Duration of Immunity Compared to Conventional COVID-19 mRNA Vaccine Booster
Published: 2024-02-05 (Crawled : 13:30) - prnewswire.com
ARCT 4 | $25.995 -1.23% -1.25% 630K
|
Health Technology
|
| O: -0.29%
H: 2.11%
C: 1.3%
covid-19 vaccine mrna therapeutics results
Vaxart Receives $9.27 Million BARDA Project NextGen Award to Prepare for Phase 2b Clinical Study Evaluating Its COVID-19 Oral Pill Vaccine Candidate
Published: 2024-01-19 (Crawled : 13:30) - globenewswire.com
VXRT | News | $0.7652 -9.15% -10.08% 1.9M
|
Health Technology
|
| O: 2.1%
H: 1.04%
C: -8.52%
covid-19 award candidate vaccine million nextgen study
Atea Pharmaceuticals Announces Positive Initial Data from Phase 2 Study for Hepatitis C Virus (HCV) and Significant Enrollment Milestone for Phase 3 SUNRISE-3 Trial for COVID-19
Published: 2024-01-08 (Crawled : 21:00) - globenewswire.com
AVIR | $3.7 0.0% 220K
|
Health Technology
|
| O: 1.61%
H: 11.43%
C: 9.52%
covid-19 hepatitis positive pharmaceuticals virus trial milestone study
CureVac Announces Positive Phase 2 Interim Data from COVID-19 Vaccine Development Program in Collaboration with GSK Providing Strong Validation of Proprietary Technology Platform
Published: 2024-01-05 (Crawled : 13:30) - biospace.com/
CVAC | $2.44 0.0% 790K
|
Health Technology
|
| O: 0.71%
H: 4.24%
C: 2.12%
covid-19 vaccine positive collaboration program technology platform
Invivyd Submits Request for Emergency Use Authorization (EUA) to U.S. FDA for VYD222 for the Pre-exposure Prevention of COVID-19 in Immunocompromised Adults and Adolescents
Published: 2024-01-03 (Crawled : 12:00) - globenewswire.com
IVVD | $2.295 -2.34% -2.4% 1.1M
|
Manufacturing
|
| O: 3.56%
H: 3.44%
C: -0.53%
vyd222 covid-19 fda authorization
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.